Research Rights. ReGenX’s direct and indirect licensors retain the fully sublicensable right under the Sublicensed Technology to grant non-exclusive research and development licenses to their Affiliates and Third Parties; provided that such development rights granted by ReGenX’s direct and indirect licensors shall not include the right to conduct clinical trials in humans in the Field or any rights to sell products in the Field.
Research Rights. Notwithstanding the provisions of Clause 4.6 the RPO shall have a non-exclusive, irrevocable, perpetual, royalty free right to utilise the Foreground IP for internal teaching and research, but for no other purpose. The RPO shall also have the right to request a non-exclusive, irrevocable, perpetual, royalty free right to utilise the Foreground IP for external research with specified third parties, to be considered by the Industry Party on a case-by-case basis. The Industry Party will give due consideration to such requests. The rights of the RPO under this Clause 4.8 are subject to the confidentiality restrictions in Clause 5 and the rules on publication in Clause 6.
Research Rights. MILLIPORE hereby grants ANAPTYSBIO, solely within the FIELD OF USE and TERRITORY, the non-exclusive right and license, under the MILLIPORE INTELLECTUAL PROPERTY and to use and modify the MATERIALS, with the right to grant sublicenses as expressly provided in this AGREEMENT, to use the MATERIALS and MILLIPORE INTELLECTUAL PROPERTY for RESEARCH PURPOSES in ANAPTYSBIO’s research facilities worldwide or the worldwide research facilities of a SUBLICENSEE or of a THIRD PARTY retained by ANAPTYSBIO or a SUBLICENSEE to perform contract research and/or contract development on behalf of ANAPTYSBIO (a “CRO”) and specifically related to ANAPTYSBIO TECHNOLOGY and/or ANAPTYSBIO PROTEINS.
Research Rights. Xxxxxx on behalf of itself and the Cornell Research Foundation (“CRFI”), Cornell University, the Memorial Sloan Kettering Cancer Center (“MSKCC”), the University of Oxford (“UO”), and the Academisch Ziekenhuis Leiden (“AZL”) retain an irrevocable, nonexclusive, and nontransferable right to practice for their own educational and research purposes, the inventions claimed under Xxxxxx Patent Rights and Xxxxxx Know-how.
Research Rights. 5/16/97 CURAGEN shall have the sole and exclusive right to use all Proprietary Intellectual Property and Research Results to conduct Genomics Research in the CURAGEN Commercialization Field. PIONEER shall have the sole and exclusive right to use all Proprietary Intellectual Property and Research Results to conduct Genomics Research in the PIONEER Commercialization Field. Both parties shall have the right to use all Proprietary Intellectual Property and Research Results to conduct Genomics Research in the Other Commercialization Field.
Research Rights. Notwithstanding the license rights granted under Section 2.1.1, PolyBioCept shall have the right to grant sublicenses under the Licensed Intellectual Property to KI and/or a KI Affiliated Hospital, their Representatives and their Third-Party contractors to Develop and Manufacture Products in the Field in the Unrestricted Territory and in the Restricted Field in the Restricted Territory solely for KI’s and a KI Affiliated Hospital’s internal research and academic purposes, including use in the treatment of patients in KI Affiliated Hospitals, provided that PolyBioCept shall not have the right to authorize KI and/or a KI Affiliated Hospital, their Representatives and their Third-Party contractors to Commercialize the Products in the Field in the Unrestricted Territory and/or in the Restricted Field in the Restricted Territory. For the avoidance of doubt, solely for purposes of this Section 2.1.3, “treatment of patients” for internal research and academic purposes will not constitute “Commercialization,” even if a patient or a Third Party compensates KI and/or a KI Affiliated Hospital for such treatment.
Research Rights. Notwithstanding the terms in Section 8(A), above, Sponsor hereby grants to Cal Poly a royalty free, worldwide, perpetual, irrevocable, non-exclusive license (without the right to sublicense) to utilize such Derivative Intellectual Property for research purposes.
Research Rights. Notwithstanding the provisions of Clause 4.7 or the grant of any exclusive licence to Project Foreground IP, the owning RUN-EU RPO or the RUN-EU RPO’s in the case of jointly owned IP shall have a non-exclusive, irrevocable, perpetual, royalty free right to utilise the Foreground IP for internal teaching and research, but for no other purpose. The rights of the RUN-EU RPO’s under this Clause 4.12 are subject to the confidentiality restrictions in Clause 5 and the rules on publication in Clause 6.
Research Rights. Verenium hereby grants to Syngenta and its Affiliates a perpetual, royalty free, world-wide license, with the right to sublicense for the purpose of conducting work by or on behalf of Syngenta or its Affiliates, under the Verenium Patent Rights and Verenium Know-How to develop, have developed, make, have made and use Biomolecules included in the Collaboration Materials expressed or produced through Microbial Expression solely for the purpose of research and development of such Biomolecules for production or expression through Transgenic Expression pursuant to the license granted in Section 2.1. For clarification, in no event shall Syngenta or its Affiliates have any license to commercialize any Biomolecules included in the Collaboration Materials expressed or produced through Microbial Expression or products based thereon.
Research Rights. Notwithstanding the provisions of Clause 4.7 or the grant of any exclusive licence to Project Foreground IP, the RPO shall have a non-exclusive, irrevocable, perpetual, royalty free right to utilise the Foreground IP for internal teaching and research, but for no other purpose. The rights of the RPO under this Clause 4.13 are subject to the confidentiality restrictions in Clause 5 and the rules on publication in Clause 6.
